News & Updates

The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.

Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.

Children with vision impairment are at higher risk of developing symptoms of depression and anxiety, according to a study, noting that surgical treatment of strabismus may improve these symptoms.

Genetic evidence from a recent study suggests that habitual coffee drinkers have an increased risk of primary open-angle glaucoma (POAG).

Patients with diabetes mellitus are at reduced risk of developing open-angle glaucoma (OAG), although the magnitude of reduction is modest, according to a study.

Treatment with brolucizumab 6 mg, dosed every 4 weeks, is not inferior to aflibercept 2 mg, dosed every 4 weeks, in previously treated participants with neovascular age-related macular degeneration (nAMD) and persistent retinal fluid, a study has shown.